S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

$11.31
-0.41 (-3.50%)
(As of 04/19/2024 ET)
Today's Range
$11.01
$11.69
50-Day Range
$9.15
$17.47
52-Week Range
$3.21
$18.33
Volume
5.26 million shs
Average Volume
4.33 million shs
Market Capitalization
$3.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.64

Iovance Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
117.8% Upside
$24.64 Price Target
Short Interest
Bearish
21.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.03mentions of Iovance Biotherapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$2.29 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.40) to ($0.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.66 out of 5 stars

Medical Sector

71st out of 907 stocks

Biological Products, Except Diagnostic Industry

8th out of 149 stocks

IOVA stock logo

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Stock Price History

IOVA Stock News Headlines

The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover (IOVA)
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
557
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$24.64
High Stock Price Target
$34.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+117.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-444,040,000.00
Pretax Margin
-37,638.01%

Debt

Sales & Book Value

Annual Sales
$1.19 million
Book Value
$2.28 per share

Miscellaneous

Free Float
250,259,000
Market Cap
$3.16 billion
Optionable
Optionable
Beta
0.62

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 50)
    J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 51)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 51)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 57)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    Vice President of Investor Relations & Public Relations
  • Ms. Tracy Winton
    Senior Vice President of Human Resources
  • Mr. Howard B. Johnson M.B.A. (Age 64)
    Chief Business Officer
  • Mr. James Ziegler M.B.A.
    Executive Vice President of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Executive VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Senior VP & Head of Digital and Information Technology

IOVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price target for 2024?

10 Wall Street analysts have issued 1-year price objectives for Iovance Biotherapeutics' stock. Their IOVA share price targets range from $17.00 to $34.00. On average, they expect the company's share price to reach $24.64 in the next year. This suggests a possible upside of 117.8% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2024?

Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of the year. Since then, IOVA shares have increased by 39.1% and is now trading at $11.31.
View the best growth stocks for 2024 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. The biotechnology company had revenue of $0.48 million for the quarter, compared to analyst estimates of $1.44 million. During the same period last year, the firm posted ($0.64) earnings per share.

What ETFs hold Iovance Biotherapeutics' stock?
What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.15%), Grimes & Company Inc. (0.01%) and Diversified Trust Co (0.01%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IOVA) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners